Effectiveness of micronized purified flavonoid fraction in early stage chronic venous disease-Clinical, Etiological, Anatomical, and Pathophysiological C0s-C1: A systematic review and meta-analysis.
Bouskela Eliete, Zolotukhin Igor, Amore Miguel et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness of micronized purified flavonoid fraction (MPFF) in patients with early stage chronic venous disease (C0s-C1). Analyzing five studies with 411 patients, the results indicated that MPFF significantly reduced pain intensity (mean change -2.3 cm) and heaviness (mean change -2.8 cm), while improving quality of life (mean change -16.0).
Key findings
- MPFF reduced pain intensity by a mean change of -2.3 cm (95% CI, -3.1 to -1.6).
- MPFF reduced heaviness by a mean change of -2.8 cm (95% CI, -3.5 to -2.1).
- MPFF improved quality of life with a mean change of -16.0 (95% CI, -20.7 to -11.3).
- Two studies reported complete resolution of symptoms for pain (100.0%) and heaviness (87.9%).
Why it matters
The findings support the use of MPFF in managing early chronic venous disease, highlighting its potential to alleviate symptoms and enhance quality of life, which is crucial for patient care.
What to keep in mind
Two studies included in the analysis had a high risk of bias, and there was frequently high heterogeneity among studies.